iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s
The RMAT designation is intended to expedite the development and evaluation of regenerative medicine therapies.
Drug Development
AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy
FDA grants Novartis’ ianalumab breakthrough therapy status for Sjögren’s disease
InterAx and Alveus collaborate on small-molecule metabolic treatment
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal
Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease
JPM26: SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody
Atara receives FDA complete response letter for Ebvallo BLA application
